The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis.

J Vasc Surg Venous Lymphat Disord · 2024 · PMC11523455 · PMID 37490950

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Compared with low-dose rivaroxaban, standard-dose rivaroxaban was not associated with an increased risk of major bleeding (HR, 1.71; 95% CI, 0.80-3.67), with a significant trend towards to increase the risk of CRNM bleeding (HR, 2.28; 95% CI, 1.40-3.74).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.